ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biosimilars"

  • Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting

    US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation

    Ting-Chun Yeh1, Yolaine Jeune-Smith 1, Eli Phillips 1, Ajeet Gajra 1 and Bruce Feinberg 1, 1Cardinal Health Specialty Solutions, Dublin, OH

    Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…
  • Abstract Number: 2406 • 2019 ACR/ARP Annual Meeting

    Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry

    Bente Glintborg 1, Stylianos Georgiadis 2, Mette Nørgaard 3, Frank Mehnert 3, Kathrine Lederballe Grøn 1, Niels Steen Krogh 4 and Merete Lund Hetland1, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 4Zitelab / DANBIO, Copenhagen, Denmark

    Background/Purpose: Marketing of biosimilar biological drugs may significantly reduce drug costs if comparable safety and efficacy of originator and the biosimilar can be documented. In…
  • Abstract Number: 205 • 2019 ACR/ARP Annual Meeting

    Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis

    Bente Glintborg 1, Rikke Ibsen 2, Rebekka Elisabeth Qwist Bilbo 3, Merete Lund Hetland1 and Jakob Kjellberg 3, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2i2minds, Aarhus, Denmark, 3VIVE, The Danish Centre for Social Science Research, Copenhagen, Denmark

    Background/Purpose: Marketing of cheaper biosimilar biological agents has created financial incentives for switching from the corresponding originator drugs (=non-medical switch). The economic benefit might potentially…
  • Abstract Number: 207 • 2019 ACR/ARP Annual Meeting

    Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

    Ambre Lauret 1, Anna Moltó 1, Vered Abitbol 2, Loriane Guterlann 3, Ornella Conort 3, Francois Chast 3, Claire Goulvestre 4, Claire Le Jeunne 5, Stanislas Chaussade 2, Christian Roux 1, Frédéric Batteux 6, Maxime Dougados 7, Yannick Allanore 1 and Jerome Avouac1, 1Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 2Paris Descartes University, Cochin Hospital, Gastroenterology department, Paris, France, 3Paris Descartes University, Cochin Hospital, Department of Pharmacy, paris, France, 4Paris Descartes University, Cochin Hospital, Immunology Laboratory, Paris, France, 5Paris Descartes University, Cochin Hospital, Internal Medicine department, Paris, France, 6Paris Descartes University, Cochin Hospital, Immunology Laborator, Paris, France, 7Cochin Hospital, Paris, France

    Background/Purpose: To determine whether the successive switches from innovator infliximab to a first then a second biosimilar infliximab, or from a first to a second…
  • Abstract Number: 977 • 2018 ACR/ARHP Annual Meeting

    Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies

    Andrew Fell1, Emma Carson1, Gillian Coyle1, Neil Martin1, Jo Walsh1 and Janet Gardner-Medwin2, 1Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, 2School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system…
  • Abstract Number: 1532 • 2018 ACR/ARHP Annual Meeting

    Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis

    Paul Emery1, Michael E Weinblatt2, Josef S. Smolen3, Edward C. Keystone4, Mark C. Genovese5, Jiri Vencovsky6, Jonathan Kay7, Evelyn Hong8 and Jeehoon Ghil8, 1University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Stanford University Medical Center, Palo Alto, CA, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, 7UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 8Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

    Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. The phase III randomized, double-blind clinical studies comparing the efficacy and…
  • Abstract Number: 1769 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India

    Aman Sharma1, Sakshi Mittal2, GSRSNK Naidu3, Saket Jha2, Manish Rathi4, Vikas Sharma2, Arghya Chattopadhyay5, Varun Dhir6, Kusum Sharma7, Ranjana Minz8, Ritambhra Nada9 and Sanjay Jain10, 1Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, 2Internal Medicine, PGIMER, Chandigarh, India, 3PGIMER, cHANDIGARH, India, 4Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 5PGIMER, Chandigarh, India, 6Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, 7Department of Medical Microbiology,, PGIMER,, Chandigarh, India, 8Department of Immunopathology,, PGIMER,, Chandigarh, India, 9Postgraduate Institute of Medical Education and Research, Chandigarh, India, 10Postgraduate Institute of Medical Education and Research, Chandigarh, India, CHANDIGARH, India

    Background/Purpose: Though rituximab(RTX) has become a standard of care for remission induction and maintenance in Granulomatosis with Polyangiitis(GPA), there is very limited data on the…
  • Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Piotr Wiland1, Sławomir Jeka2, Eva Dokoupilová3,4, Juan Manuel Miranda Limón5, Julia Jauch-Lembach6, Anjali Thakur6, Halimuniyazi Haliduola6 and Norman B Gaylis7, 1Wrocław Medical University, Wrocław, Poland, 2Collegium Medicum UMK, 2nd University Hospital, Bydgoszcz, Poland, 3MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic, 4Faculty of Pharmacy, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic, 5RM Pharma Specialists, Mexico City, Mexico, 6Hexal AG, Holzkirchen, Germany, 7Arthritis & Rheumatic Disease Specialties, Aventura, FL

    Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…
  • Abstract Number: 2154 • 2018 ACR/ARHP Annual Meeting

    Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes

    Hubert Marotte1, NADIR MAMMAR2 and Bruno Fautrel3, 1University Hospital of Saint Etienne,, Saint Etienne, France, 2Pfizer, PARIS, France, 3Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S 1136, Sorbonne Université, GRC-UPMC 08, Paris, France

    Background/Purpose: CT-P13 was the first monoclonal antibody biosimilar to infliximab (IFX) approved in France. Reflect trial has been set up to evaluate in real life…
  • Abstract Number: 2367 • 2018 ACR/ARHP Annual Meeting

    Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)

    Marc Scherlinger1,2,3, Vincent Germain1, Emmanuel Langlois4 and Thierry Schaeverbeke5, 1Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, 2FHU ACRONIM, Bordeaux, France, 3Rheumatology, UMR CNRS 5164 - Immunoconcept, France, Bordeaux, France, 4CNRS-UMR 5116 Centre Emile Durkheim, Bordeaux, France, 5Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France

    Background/Purpose: Biosimilars represent major potential savings while preserving treatment quality. However, few data are known on how to address the switch from originator to biosimilar…
  • Abstract Number: 2384 • 2018 ACR/ARHP Annual Meeting

    Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany

    Jens Klotsche1, Martina Niewerth1, Gerd Horneff2 and Kirsten Minden3,4, 1Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, 2Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, 3Charité–Universitätsmedizin Berlin, Berlin, Germany, 4German Rheumatism Research Center, Berlin, Germany

    Background/Purpose: The first biosimilars have been approved for the treatment of juvenile idiopathic arthritis (JIA) in the last two years. To date, only a few…
  • Abstract Number: 2515 • 2018 ACR/ARHP Annual Meeting

    Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study

    Chang-Hee Suh1, Dae-Hyun Yoo2, Won Park3, Seung-Cheol Shim4, Sang-Joon Lee5, Yun Ju Bae5, Sang Eun Han5 and Sang Mi Lee5, 1Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 3Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), 5CELLTRION, Inc., Incheon, Korea, Republic of (South)

    Background/Purpose: CT-P10 is a biosimilar of the reference rituximab (RTX) and has been approved by several regulatory agencies including EMA. Pharmacokinetic and therapeutic equivalence from…
  • Abstract Number: 2521 • 2018 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78

    Stanley Cohen1, Alan J. Kivitz2, Michael Tee3, Carol Cronenberger4, Min Zhang5, Sarah Hackley6, Karl Schumacher7 and Muhammad I. Rehman8, 1Metroplex Clinical Research Center, LLC, Dallas, TX, 2Altoona Center for Clinical Research, Duncansville, PA, 3Department of Medicine, Medical Center Manila and University of the Philippines, Manila, Philippines, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, La Jolla, CA, 6Pfizer Ltd, Sandwich, United Kingdom, 7Global Clinical Development, Biopharmaceuticals, Sandoz Biopharmaceuticals, Holzkirchen, Germany, 8Pfizer Inc, Andover, MA

    Background/Purpose: PF-06438179/GP1111 (IFX-PF) is an infliximab (IFX) biosimilar for the treatment of immune-mediated inflammatory diseases, including RA. This randomized, double-blind, comparative clinical study evaluated the…
  • Abstract Number: 2522 • 2018 ACR/ARHP Annual Meeting

    Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

    Stanley Cohen1, Niklas Czeloth2, Eric Lee3, Piotr A. Klimiuk4, Nuala Peter5 and Girish Jayadeva2, 1Metroplex Clinical Research Center, Dallas, TX, 2Boehringer Ingelheim, Ingelheim a.R., Germany, Ingelheim, Germany, 3Inland Rheumatology, Upland, CA, 4Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, 5Boehringer Ingelheim, Biberach a.d.R., Germany, Ingelheim a.R., Germany

    Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…
  • Abstract Number: 2526 • 2018 ACR/ARHP Annual Meeting

    Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys

    Katie Robinson and Robert Esgro, Vindico Medical Education, Thorofare, NJ

    Background/Purpose: With the recent introduction of biosimilars in the US market, providers lack knowledge of how these agents compare to reference biologics and the implications…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology